Marlboro cigarette maker Altria is in early stage talks to acquire Canadian cannabis producer Cronos, as it seeks to diversify its business beyond traditional smokers, people familiar with the matter told the Financial Times.
A takeover of Cronos by Altria amid spreading decriminalisation would rank among the largest investments in the budding pot industry. Shares in Cronos, which grows and distributes cannabis, climbed 14% in New York on Monday to $10.39, giving the Canadian company a market capitalisation of $1.9bn.
Cronos said in a statement after the market closed that it was “engaged in discussions concerning a potential investment” by Altria. The statement added: “No agreement has been reached with respect to any such transaction and there can be no assurance such discussions will lead to an investment or other transaction involving the companies.”
Featured News
Trump Nominates Olivia Trusty for FCC Commissioner Role Ahead of Inauguration
Jan 16, 2025 by
CPI
Lawyers Claim eXp’s Settlement Tactics Hurt Antitrust Case Potential
Jan 16, 2025 by
CPI
Amex GBT Pushes Back Against DOJ Lawsuit Over CWT Acquisition
Jan 16, 2025 by
CPI
Belgium Opens Antitrust Probe into AB InBev’s Market Practices
Jan 16, 2025 by
CPI
Tech Groups Sue CFPB Over New Rule on Digital Wallet Oversight
Jan 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand